Canadian Journal of Gastroenterology (Jan 2011)

Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial

  • Remo Panaccione,
  • Edward V Loftus,
  • David Binion,
  • Kevin McHugh,
  • Shamsul Alam,
  • Naijun Chen,
  • Benoît Guérette,
  • Parvez Mulani,
  • Jingdong Chao

DOI
https://doi.org/10.1155/2011/724813
Journal volume & issue
Vol. 25, no. 8
pp. 419 – 425

Abstract

Read online

OBJECTIVE: To evaluate open-label adalimumab therapy for clinical effectiveness, fistula healing, patient-reported outcomes and safety in Canadian patients with moderate to severe Crohn’s disease (CD) who were either naive to or previously exposed to antitumour necrosis factor (anti-TNF) therapy.